Huntington’s Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), by treatment (symptomatic therapy, disease-modifying therapy), by end-users (hospital and others) - Global Forecast Till 2027
ID: MRFR/Pharma/5466-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
Global Huntington’s Disease Treatment Market is expected to rise steadily at a CAGR of 40% during forecast period of 2018-2023.
Huntington’s Disease is a genetic disorder that causes degeneration of nerve cells in brain. The degeneration of brain cells controls movement, intellectual ability and behaviour of that person. This disease normally appears at the age of 30-50 and gets worsen within 10-25 years of time. Huntington’s disease is fatal and there is no cure for this disease.
The Global Huntington’s Disease Treatment Market is largely driven by factors such as increased adoption of novel therapeutics, increase in R&D activities, rise in target population and favourable government initiatives. The huntington’s disease pipeline will see the new development in coming years as the disease modifying drugs transforms the market landscape. Many key players in market are engaged in development of new drug products for the treatment of huntington disease. At present, more than 20 products are being studied for treatment for huntington’s disease in various stages of clinical trials.
However certain factors that can hamper the growth of this market in near future are lack of awareness regarding genetic disorders and alternative treatment plans.
Segmentation:
Global Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. On basis of drug type the Global Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market. The European Huntington’s Disease Treatment Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Huntington’s Disease Treatment Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The huntington’s disease treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players:
Some of the key players in the Global Huntington’s Disease Treatment Market are Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.
Regional Market Summary
Global Huntington’s Disease Treatment Market Share (%), by Region, 2017 
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon
Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.
The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.
Global Huntington’s Disease Treatment Market by Drug Type:
- Tetrabenazine
- Deutetrabenazine
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Chlorpromazine
- Haloperidol
- Risperidone
- Olanzapine
- Clozapine
- Other
Global Tinea Corporis Market, by Treatment:
- Symptomatic Therapy
- Disease-Modifying Therapy
Global Tinea Corporis Market, by End-Users:
- Hospital
- Clinics
- Online Pharmacies
- Retail Pharmacies
- Others
Global Tinea Corporis Market, by Region:
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- The Middle East & Africa
- Middle East
- Africa
Global Tinea Corporis Market, by Key Players:
- Alnylam Pharmaceuticals Inc
- AmpliPhi Biosciences Corp
- Ceregene Inc
- Lundbeck
- Prana Biotechnology Limited
- Teva Pharmaceutical Industries Ltd
- Cortex Pharmaceuticals Inc
- Vertex Pharmaceuticals Incorporated
- Auspex Pharmaceuticals
- SOM Biotech
- GlaxoSmithKline
- Siena Biotech
- Raptor Pharmaceutical
- Pfizer
- Palobiofarma
- Omeros
- Ipsen
- Valeant Pharmaceuticals International Inc
Intended Audience:
- Manufacturers and Suppliers
- Hospitals and Clinics
- Laboratories and Associations
- Research and Development (R&D) Companies
- Government research institutes
- Academic institutes and universities
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 40% (2018-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug type, Treatment and End-users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Huntington’s Disease Treatment Market, by Drug Type
6.1 Introduction
6.2 Tetrabenazine
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3 Deutetrabenazine
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.4 Selective Serotonin Reuptake Inhibitor (SSRI)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.5 Chlorpromazine
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.6 Haloperidol
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.7 Risperidone
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.8 Olanzapine
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.9 Clozapine
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.10 Other
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 7. Global Huntington’s Disease Treatment Market, by Treatment
7.1 Introduction
7.2 Symptomatic therapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3 Disease-Modifying therapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 8. Global Huntington’s Disease Treatment Market, by End-Users
8.1 Introduction
8.2 Hospital
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8.3 Clinics
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8.4 Retail Pharmacies
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8.5 Online Pharmacies
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8.6 Others
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 9. Global Huntington’s Disease Treatment Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
Chapter 11. Company Profiles
11.1 Pfizer, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Alnylam Pharmaceuticals Inc
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 AmpliPhi Biosciences Corp
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Ceregene Inc
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Prana Biotechnology Limited
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Teva Pharmaceutical Industries Ltd
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Cortex Pharmaceuticals Inc
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Vertex Pharmaceuticals Incorporated
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Auspex Pharmaceuticals
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 SOM Biotech
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 GlaxoSmithKline
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Siena Biotech
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Raptor Pharmaceutical
11.13.1 Overview
11.13.2 Product Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.14 Palobiofarma
11.14.1 Overview
11.14.2 Product Overview
11.14.3 Financials
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.15 Omeros
11.15.1Overview
11.15.2 Product Overview
11.15.3 Financials
11.15.4 Key Developments
11.15.5 SWOT Analysis
11.16 Ipsen
11.16.1 Overview
11.16.2 Product Overview
11.16.3 Financials
11.16.4 Key Developments
11.16.5 SWOT Analysis
11.17 Valeant Pharmaceuticals International Inc
11.17.1 Overview
11.17.2 Product Overview
11.17.3 Financials
11.17.4 Key Developments
11.17.5 SWOT Analysis
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Global Huntington’s Disease Treatment Market
Chapter 13. Appendix
LIST OF TABLES
Table 1 Global Huntington’s Disease Treatment Market Synopsis, 2020-2027
Table 2 Global Huntington’s Disease Treatment Market Estimates and Forecast, 2020-2027 (USD Million)
Table 3 Global Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 4 Global Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 5 Global Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 6 Global Huntington’s Disease Treatment Market, by Region, 2020-2027(USD Million)
Table 7 North America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 8 North America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 9 North America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 10 North America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 11 US: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 12 US: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 13 US: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 14 US: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 15 Canada: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 16 Canada: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 17 Canada: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 18 Canada: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 19 South America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 20 South America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 21 South America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 22 South America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 23 Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 24 Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 25 Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 26 Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 27 Western Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 28 Western Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 29 Western Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 30 Western Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 31 Eastern Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 32 Eastern Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 33 Eastern Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 34 Eastern Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 35 Asia-Pacific: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 36 Asia-Pacific: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 37 Asia-Pacific: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 38 Asia-Pacific: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
Table 39 Middle East & Africa: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)
Table 40 Middle East & Africa: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 41 Middle East & Africa: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)
Table 42 Middle East & Africa: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Huntington’s Disease Treatment Market
Figure 3 Segmentation Market Dynamics for Global Huntington’s Disease Treatment Market
Figure 4 Global Huntington’s Disease Treatment Market Share, by Drug Type, 2020(%)
Figure 5 Global Huntington’s Disease Treatment Market Share, by Treatment, 2020(%)
Figure 6 Global Huntington’s Disease Treatment Market Share, by End-Users, 2020(%)
Figure 7 Global Huntington’s Disease Treatment Market Share, by Region, 2020(%)
Figure 8 North America: Huntington’s Disease Treatment Market Share, by Country, 2020(%)
Figure 9 Europe: Huntington’s Disease Treatment Market Share, by Country, 2020(%)
Figure 10 Asia-Pacific: Huntington’s Disease Treatment Market Share, by Country, 2020(%)
Figure 11Middle East & Africa: Huntington’s Disease Treatment Market Share, by Country,2020(%)
Figure 12 Global Huntington’s Disease Treatment Market: Company Share Analysis, 2020(%)
Figure 13 Pfizer, Inc: Key Financials
Figure 14 Pfizer, Inc: Segmental Revenue
Figure 15 Pfizer, Inc: Geographical Revenue
Figure 16 Alnylam Pharmaceuticals Inc: Key Financials
Figure 17 Alnylam Pharmaceuticals Inc: Segmental Revenue
Figure 18 Alnylam Pharmaceuticals Inc: Geographical Revenue
Figure 19 AmpliPhi Biosciences Corp: Key Financials
Figure 20 AmpliPhi Biosciences Corp: Segmental Revenue
Figure 21 AmpliPhi Biosciences Corp: Geographical Revenue
Figure 22 Ceregene Inc: Key Financials
Figure 23 Ceregene Inc: Segmental Revenue
Figure 24 Ceregene Inc: Geographical Revenue
Figure 25 Prana Biotechnology Limited.: Key Financials
Figure 26 Prana Biotechnology Limited.: Segmental Revenue
Figure 27 Prana Biotechnology Limited.: Geographical Revenue
Figure 28 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 29 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 30 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 31 Cortex Pharmaceuticals Inc: Key Financials
Figure 32 Cortex Pharmaceuticals Inc: Segmental Revenue
Figure 33 Cortex Pharmaceuticals Inc: Geographical Revenue
Figure 34 Vertex Pharmaceuticals Incorporated: Key Financials
Figure 35 Vertex Pharmaceuticals Incorporated: Segmental Revenue
Figure 36 Vertex Pharmaceuticals Incorporated: Geographical Revenue
Figure 37 Auspex Pharmaceuticals: Key Financials
Figure 38 Auspex Pharmaceuticals: Segmental Revenue
Figure 39 Auspex Pharmaceuticals: Geographical Revenue
Figure 40 SOM Biotech: Key Financials
Figure 41 SOM Biotech: Segmental Revenue
Figure 42 SOM Biotech: Geographical Revenue
Figure 43 GlaxoSmithKline: Key Financials
Figure 44 GlaxoSmithKline: Segmental Revenue
Figure 45 GlaxoSmithKline: Geographical Revenue
Figure 46 Siena Biotech: Key Financials
Figure 47 Siena Biotech: Segmental Revenue
Figure 48 Siena Biotech: Geographical Revenue
Figure 49 Raptor Pharmaceutical.: Key Financials
Figure 50 Raptor Pharmaceutical.: Segmental Revenue
Figure 51 Raptor Pharmaceutical.: Geographical Revenue
Figure 52 Palobiofarma: Key Financials
Figure 53 Palobiofarma: Segmental Revenue
Figure 54 Palobiofarma: Geographical Revenue
Figure 55 Omeros: Key Financials
Figure 56 Omeros: Segmental Revenue
Figure 57 Omeros: Geographical Revenue
Figure 58 Ipsen: Key Financials
Figure 59 Ipsen: Segmental Revenue
Figure 60 Ipsen: Geographical Revenue
Figure 61 Valeant Pharmaceuticals International Inc: Key Financials
Figure 62 Valeant Pharmaceuticals International Inc: Segmental Revenue
Figure 63 Valeant Pharmaceuticals International Inc: Geographical Revenue